Spheres Pty News Today

/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced that the Brazilian National Agency of...

/PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced today with its shareholder, Grand...

SIR-Spheres Y-90 resin microspheres are the first therapeutic radiopharmaceutical approved by the NMPA in 2022 WOBURN, Mass., Feb. 9, 2022 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading

Press release content from PR Newswire. The AP news staff was not involved in its creation.

CLEVELAND, Aug. 5, 2021 /PRNewswire/ -- MIM Software Inc., a leading global provider of medical imaging software, announced today it has received CE Mark approval for MAA voxel-based SPECT/CT

Press release content from PR Newswire. The AP news staff was not involved in its creation. DOORwaY-90 study for SIR-Spheres® therapy as first-line treatment for hepatocellular carcinoma enrolls first patient May 10, 2021 GMT Sirtex DOORwaY-90 Study Logo First prospective multicenter U.S.-based trial for indication expansion of SIR-Spheres® Y-90 resin microspheres taking place in 15 sites across the U.S. WOBURN, Mass., May 10, 2021 /PRNewswire/ -- Sirtex Medical (“Sirtex”), a leading manu...

Share this article Share this article WOBURN, Mass., April 19, 2021 /PRNewswire/ -- Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company developing groundbreaking therapies in endovascular embolization, announced that the first patient has been enrolled in the LAVA Study to evaluate the safety and effectiveness of the BlackSwan Lava™ liquid embolic system (LES) for the embolic treatment ...

Sirtex Medical receives positive recommendation from National Institute for Health and Care Excellence (NICE) for selective internal radiation therapy (SIRT) using SIR-Spheres WOBURN, Mass., Feb. 26, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, received positive guidance from the National Institute for Health and Care Excellence (NICE) regarding the use of selection internal radiation therapy (SIRT) with SIR-Spheres Y-9...

Sirtex Medical announces collaboration update with OncoSec Medical News provided by Share this article  TAVO™ for the treatment of advanced melanoma WOBURN, Mass., Jan. 19, 2021 /PRNewswire/ -- Sirtex Medical US Holdings, Inc. ("Sirtex"), a leading manufacturer of targeted cancer therapies, announced an advancement in its strategic collaboration with OncoSec Medical, Inc. (NASDAQ: ONCS) relating to OncoSecs lead product candidate TAVO™ (tavokinogene telseplasmid) and its electroporation (...

Share this article Share this article PENNINGTON, N.J. and SAN DIEGO, Jan. 19, 2021 /PRNewswire/ -- OncoSec Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec") today announced it entered into an agreement with Sirtex Medical, Inc. (Sirtex) granting Sirtex an option to non-exclusively co-promote the Companys lead product candidate, TAVO™ (tavokinogene telseplasmid) in anti-PD-1 checkpoint refractory metastatic melanoma in the U.S. By entering into this co-promotion, OncoSec intends...